Skip to main content
Premium Trial:

Request an Annual Quote

GenDx Gets South Korean Clearance for HLA Typing Workflow

NEW YORK (GenomeWeb) – GenDx announced today that it has received IVD marking from South Korean regulators for its NGSgo human leukocyte antigen (HLA) typing workflow used in transplant medicine.

According to the company, the workflow is now cleared by the South Korean Ministry of Food and Drug Safety for the typing of HLA-A, B, C, DRB1, and DQB1 by next-generation sequencing on Illumina Miseq platforms, followed by analysis with GenDx's NGSengine software.

HLA genes code for cell-surface antigen-presenting proteins, and HLA typing is an important genetic analysis in assessing compatibility between donor and recipient in stem cell and solid organ transplants since mismatches can result in transplant failure.

"It took a great deal of work to complete the registration, and we are proud to be the first supplier that can offer IVD NGS products for HLA typing in South Korea," GenDx CEO Wietse Mulder said in a statement.

Last week, GenDx received CE-IVD marking for its its line of PCR-based chimerism monitoring products for use in stem cell or bone marrow transplantation.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.